IPO registrations (S-1, F-1) · Registrants

Passage BIO, Inc.

SEC CIK
1787297 · filings on EDGAR ↗
Registration
Form S-1, first filed 2020-02-03, last 2021-01-19; 2 initial registrations, 2 amendments
Outcome
Final prospectus filed 2020-02-28; declared effective 2020-02-27
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, Philadelphia, PA 19103
EIN
82-2729751
Ticker
PASG (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
Passage BIO, Inc. on the corporate pages

Offering terms

Proposed price range
$16.00–$18.00 per share (S-1/A filed 2020-02-27)
Final price
$18.00 per share, within the range (424B4 filed 2020-02-28, an initial public offering)
Shares sold
12,000,000
Gross proceeds
$216,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol PASG
Lead underwriters
J.P. Morgan; Goldman Sachs; Cowen
Syndicate
Chardan

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 10

FiledFormWhat it isName as filedEDGAR
2020-02-03S-1S-1 (registration)Passage BIO, Inc.0001047469-20-000652 ↗
2020-02-18S-1/AS-1/A (amendment)Passage BIO, Inc.0001047469-20-000894 ↗
2020-02-27S-1/AS-1/A (amendment)Passage BIO, Inc.0001047469-20-001071 ↗
2020-02-27S-1MEFS-1MEF (added securities)Passage BIO, Inc.0001047469-20-001096 ↗
2020-02-27EFFECTEFFECT (declared effective)Passage BIO, Inc.9999999995-20-000432 ↗
2020-02-28424B4424B4 (final prospectus)Passage BIO, Inc.0001047469-20-001117 ↗
2021-01-19S-1S-1 (registration)Passage BIO, Inc.0001104659-21-005296 ↗
2021-01-21EFFECTEFFECT (declared effective)Passage BIO, Inc.9999999995-21-000233 ↗
2021-01-22424B1424B1 (final prospectus)Passage BIO, Inc.0001104659-21-006683 ↗
2022-04-14EFFECTEFFECT (declared effective)Passage BIO, Inc.9999999995-22-000975 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2020-02-27S-1/Aregistration statement$16.00–$18.0010,000,000-Nasdaq PASG4primary document; range, shares headline, cover names 4document ↗
2020-02-28424B4final prospectus$18.0012,000,000$216,000,000Nasdaq PASG4primary document; price sentence, shares headline, proceeds table, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Cale Edgar B.OfficerGC and Corporate Secretary; GC & Corporate Secretary; GC & CORPORATE SECRETARY; Interim CEO, GC & Corp. Sec.132020–2025
Countouriotis AthenaDirector102020–2026
FHMLS IX, L.L.C.TenPercentOwner22020
FHMLS IX, L.P.TenPercentOwner22020
Fotopoulos AlexandrosOfficerChief Technical Officer112020–2023
Frazier Life Sciences IX, L.P.TenPercentOwner22020
Goldsmith Bruce ADirector,OfficerCEO and President72020–2022
Heron Patrick JDirector,TenPercentOwner32020
Islam SaqibDirector82020–2025
Kapadia SandipDirector102020–2026
Morris Richard StevenOfficerChief Financial Officer52020–2021
ORBIMED ADVISORS LLCTenPercentOwner182020–2025
OrbiMed Capital GP VII LLCTenPercentOwner182020–2025
Quigley Jill M.OfficerChief Operating Officer72020–2021
Ratcliffe LiamDirector62020–2021
Romano GaryOfficerChief Medical Officer42020–2021
SQUINTO STEPHEN PDirector,OfficerHead of Research and Dev22020
Topper James NTenPercentOwner22020
Versant Vantage I GP-GP, LLCTenPercentOwner22020
Versant Vantage I GP, L.P.TenPercentOwner22020
Versant Vantage I, L.P.TenPercentOwner22020
Versant Venture Capital VI, L.P.TenPercentOwner22020
Versant Ventures VI GP-GP, LLCTenPercentOwner22020
Versant Ventures VI GP, L.P.TenPercentOwner22020
Woiwode ThomasDirector; Director,TenPercentOwner82020–2023
Yamada TadatakaDirector42020–2021
GOWEN MAXINEDirector92021–2026
Salinas Eliseo OresteOfficerChief Res. & Develop Officer32021–2022
Porter DerrellDirector72021–2026
Burkavage BrianOfficerController12021
Toernsen Monika MariaOfficerChief Commercial Officer52021–2022
King SimonaOfficerChief Financial Officer92021–2023
Forman Mark SOfficerChief Medical Officer; CHIEF MEDICAL OFFICER82022–2024
Kamarck Michael E.Director32022–2023
Chou WilliamDirector,OfficerChief Executive Officer; President and CEO; PRESIDENT AND CEO82022–2026
Borthwick KathleenOfficerCFO; SVP, Interim CFO; SVP, INTERIM CFO102023–2026
Sondhi DolanDirector52023–2026
Lynx1 Capital Management LPTenPercentOwner62024–2026
Nichols WestonTenPercentOwner62024–2026
Kassberg Thomas RichardDirector42024–2026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2019-09-06Passage BIO, Inc.Other Health Care$110,000,000$109,999,974151

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationPassage Bio, Inc.PAState business registriesname and state
Form D issuerPassage BIO, Inc.PAForm D private offeringsCIK (EXACT)
SEC filerPassage BIO, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerPassage Bio, Inc.PATrademarks (USPTO)name and state

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), PA first:

More with this interest.

In other datasets, the same topic (Health) in PA:

Interests: Biological Products, (No Diagnostic Substances) · Health